Navigation Links
Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
Date:1/26/2010

STOCKHOLM, January 26 /PRNewswire/ -- Eribis Pharmaceuticals AB - part of the Karolinska Development portfolio - announced today that it has received follow-on financial investment enabling the company to continue its clinical development program. Based on cardio-protective effects, Eribis' candidate drug has the potential to become an important new therapy for treating acute coronary syndrome (ACS) and reperfusion injury (damage to tissue caused when blood supply returns after a period of ischemia), as well as for surgical preconditioning. The new round of investment from Karolinska Development AB will allow Eribis to strengthen the preclinical material.

In studies to date, Eribis' novel peptide therapy has shown excellent Cardio-protective effects in conditions of ACS and reperfusion. Potential benefits of the candidate drug include a decrease in the amount of cardiac tissue damage, an extension of the window of time available for treatment of ischemic conditions and a reduction of cardiovascular complications such as heart failure.

Eribis Pharmaceutical's CEO, Herman Krapf, said, "We are delighted that Karolinska Development continues to show confidence in our development program. This latest round of financing comes after strong preclinical results and means we can now move forward towards the clinical program. Successful development offers significant market potential as there is an urgent need for new and improved therapies in the area of cardio-protection."

About Acute Coronary Syndrome

Cardiovascular disorders are the leading cause of mortality worldwide and remain an area of unmet medical needs. Acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute myocardial ischaemia (chest pain due to insufficient blood supply to the heart muscle that results from coronary artery disease). The consequence of an ACS event is destruction of the heart tissue due to reduced blood flow to the heart. Following recovery from an episode of ACS, patients continue to be at heightened risk of heart attack and stroke.

About Eribis Pharmaceuticals

Eribis Pharmaceuticals is focused on the development of novel drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, as well as surgical preconditioning. The company has unique competence in the development of peptides for pharmacological use. Eribis' novel peptide candidate drug represents a new drug category aimed at meeting the market need for new and improved treatment in the field of cardio-protection.Eribis is a Karolinska Development AB portfolio company.

http://www.eribispharma

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe. Using a unique, highly cost-efficient business model, the management team guides the commercialization of world-class life science innovations, helping to shape the next-generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first-in-class products.

    http://www.karolinskadevelopment.com

    For more information, please contact:
    Herman Krapf CEO
    Herman.krapf@eribispharma.se
    +46-70-666-50-95

SOURCE Eribis Pharmaceuticals AB


'/>"/>
SOURCE Eribis Pharmaceuticals AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):